ML-7 amplifies the quinocetone-induced cell death through akt and MAPK-mediated apoptosis on HepG2 cell line

被引:7
作者
Zhou, Yan [1 ]
Zhang, Shen [1 ]
Deng, Sijun [1 ]
Dai, Chongshan [1 ]
Tang, Shusheng [1 ]
Yang, Xiayun [1 ]
Li, Daowen [1 ]
Zhao, Kena [1 ]
Xiao, Xilong [1 ]
机构
[1] China Agr Univ, Coll Vet Med, Dept Pharmacol & Toxicol, Beijing 100094, Peoples R China
关键词
Akt; HepG2; apoptosis; ML-7; quinocetone; MAPK; LIGHT-CHAIN KINASE; ACTIVATED PROTEIN-KINASES; CANCER DRUG DISCOVERY; SPRAGUE-DAWLEY RATS; OLAQUINDOX IN-VITRO; SIGNALING PATHWAY; P38; MAPK; PI3K/AKT PATHWAY; ANTI-APOPTOSIS; PROLIFERATION;
D O I
10.3109/15376516.2015.1090513
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
The study aims at evaluating the combination of the quinocetone and the ML-7 in preclinical hepatocellular carcinoma models. To this end, the effect of quinocetone and ML-7 on apoptosis induction and signaling pathways was analyzed on HepG2 cell lines. Here, we report that ML-7, in a nontoxic concentration, sensitized the HepG2 cells to quinocetone-induced cytotoxicity. Also, ML-7 profoundly enhances quinocetone-induced apoptosis in HepG2 cell line. Mechanistic investigations revealed that ML-7 and quinocetone act in concert to trigger the cleavage of caspase-8 as well as Bax/Bcl-2 ratio up-regulation and subsequent cleavage of Bid, capsases-9 and -3. Importantly, ML-7 weakened the quinocetone-induced Akt pathway activation, but strengthened the phosphorylation of p-38, ERK and JNK. Further treatment of Akt activator and p-38 inhibitor almost completely abolished the ML-7/quinocetone-induced apoptosis. In contrast, the ERK and JNK inhibitor aggravated the ML-7/quinocetone-induced apoptosis, indicating that the synergism critically depended on p-38 phosphorylation and HepG2 cells provoke Akt, ERK and JNK signaling pathways to against apoptosis. In conclusion, the rational combination of quinocetone and ML-7 presents a promising approach to trigger apoptosis in hepatocellular carcinoma, which warrants further investigation.
引用
收藏
页码:11 / 21
页数:11
相关论文
共 51 条
[1]   Perturbations of the AKT signaling pathway in human cancer [J].
Altomare, DA ;
Testa, JR .
ONCOGENE, 2005, 24 (50) :7455-7464
[2]   Targeting Apoptosis Pathways for New Cancer Therapeutics [J].
Bai, Longchuan ;
Wang, Shaomeng .
ANNUAL REVIEW OF MEDICINE, VOL 65, 2014, 65 :139-155
[3]   p38 MAPK in development and cancer [J].
Bradham, Cynthia ;
McClay, David R. .
CELL CYCLE, 2006, 5 (08) :824-828
[4]   The MAPK Pathway Across Different Malignancies: A New Perspective [J].
Burotto, Mauricio ;
Chiou, Victoria L. ;
Lee, Jung-Min ;
Kohn, Elise C. .
CANCER, 2014, 120 (22) :3446-3456
[5]   Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy [J].
Chang, F ;
Lee, JT ;
Navolanic, PM ;
Steelman, LS ;
Shelton, JG ;
Blalock, WL ;
Franklin, RA ;
McCubrey, JA .
LEUKEMIA, 2003, 17 (03) :590-603
[6]   Investigation of the genotoxicity of quinocetone, carbadox and olaquindox in vitro using Vero cells [J].
Chen, Qian ;
Tang, Shusheng ;
Jin, Xi ;
Zou, Jiajie ;
Chen, Kaipao ;
Zhang, Ting ;
Xiao, Xilong .
FOOD AND CHEMICAL TOXICOLOGY, 2009, 47 (02) :328-334
[7]   Myosin light chain kinase is responsible for high proliferative ability of breast cancer cells via anti-apoptosis involving p38 pathway [J].
Cui, Wen-jing ;
Liu, Yi ;
Zhou, Xiao-lei ;
Wang, Feng-ze ;
Zhang, Xiao-dong ;
Ye, Li-hong .
ACTA PHARMACOLOGICA SINICA, 2010, 31 (06) :725-732
[8]   MAPK pathways in radiation responses [J].
Dent, P ;
Yacoub, A ;
Fisher, PB ;
Hagan, MP ;
Grant, S .
ONCOGENE, 2003, 22 (37) :5885-5896
[9]   Liver tumor development: c-Jun antagonizes the proapoptotic activity of p53 [J].
Eferl, R ;
Ricci, R ;
Kenner, L ;
Zenz, R ;
David, JP ;
Rath, M ;
Wagner, EF .
CELL, 2003, 112 (02) :181-192
[10]   Inhibiting myosin light chain kinase induces apoptosis in vitro and in vivo [J].
Fazal, F ;
Gu, LZ ;
Ihnatovych, I ;
Han, Y ;
Hu, W ;
Antic, N ;
Carreira, F ;
Blomquist, JF ;
Hope, TJ ;
Ucker, DS ;
de Lanerolle, P .
MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (14) :6259-6266